OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
-585.2%+60.2 pts over 5 years
Net margin
-240.1%+402.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1181.3% | +69.0% | -10.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -38.2% | -142.6% | -17.5% | |
| Return on assets | – | -103.4% | -14.3% | |
| Current ratio | 14.04 | 3.39 | 8.97 | |
| Capex to revenue | – | 1.0% | 0.0% | |
| Diluted shares | 10M | 58M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ovid Therapeutics generated $313.91M from operations and spent $1.52M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$313.91M
Used
$1.52M
Capital expenditure$1.52M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-240.1%
×Asset turnover0.06×
×Equity multiplier1.22×
=Return on equity, FY2025-17.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -240.1% | 0.06× | 1.22× | -17.5% |
| FY2024 | -4670.1% | 0.00× | 1.51× | -33.9% |
| FY2023 | -13351.8% | 0.00× | 1.36× | -47.6% |
| FY2022 | -3604.7% | 0.01× | 1.12× | -34.7% |
| FY2021 | 58.9% | 1.54× | 1.21× | 110.0% |
| FY2020 | -642.3% | 0.16× | 1.38× | -142.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$17.41M
- Cash generatingOperating cash flow above zero-$38.33M
- Return on assets improvedROA up on the prior year-18.4% → -18.9%
- Earnings backed by cashOperating cash flow above net income-$38.33M vs -$17.41M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.32 → 8.97
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.08